Target Name: CCT6B
NCBI ID: G10693
Review Report on CCT6B Target / Biomarker Content of Review Report on CCT6B Target / Biomarker
CCT6B
Other Name(s): testis-specific Tcp20 | chaperonin containing TCP1, subunit 6B (zeta 2) | testis-specific protein TSA303 | chaperonin containing TCP1 subunit 6B | CCT6B variant 1 | Testis-specific protein TSA303 | CCT-zeta-like | CCTZ-2 | Testis-specific Tcp20 | chaperonin-containing T-complex polypeptide 1, subunit 6B | TSA303 | TCP-1-zeta-2 | Chaperonin containing TCP1 subunit 6B, transcript variant 1 | Chaperonin-containing T-complex polypeptide 1, subunit 6B | TCPW_HUMAN | CCT-zeta-2 | T-complex protein 1 subunit zeta-2 (isoform 1) | T-complex protein 1 subunit zeta-2 | TCP-1-zeta-like | Cctz2

CCT6B: A Potential Drug Target for Testicular Cancer

CCT6B, also known as testis-specific TCP20, is a protein that is expressed in the testes and is involved in the development and maintenance of normal testicular function. It is a member of the TCP20 family, which is a group of proteins that are involved in cell signaling and division.

Recent studies have identified CCT6B as a potential drug target for the treatment of testicular cancer, as well as a biomarker for monitoring the effectiveness of chemotherapy.

The protein CCT6B is synthesized in the testes and is involved in the development and maintenance of normal testicular function. It is a member of the TCP20 family, which is a group of proteins that are involved in cell signaling and division. CCT6B is expressed in the testes, and it has been shown to play a role in the development and maintenance of normal testicular function.

One of the key functions of CCT6B is its role in the development and maintenance of normal testicular histological structure. CCT6B has been shown to be involved in the regulation of cell proliferation and in the development of normal testicular tissue structure.

In addition to its role in normal testicular development, CCT6B has also been shown to be involved in the regulation of testicular signaling pathways. It has been shown to be involved in the regulation of the androgen receptor, which is a key regulator of testicular development and function.

Recent studies have also identified CCT6B as a potential drug target for the treatment of testicular cancer. testicular cancer is a particularly aggressive form of cancer, and there is a high need for effective treatments that can specifically target this disease. CCT6B has been shown to be involved in the regulation of cell signaling pathways, which may make it an attractive target for the development of new therapies for testicular cancer.

In addition to its potential as a drug target, CCT6B has also been identified as a biomarker for the treatment of testicular cancer. The ability to monitor the expression of CCT6B in testicular tissue can be used to assess the effectiveness of chemotherapy, which is a key part of the treatment for many forms of cancer.

Overall, CCT6B is a protein that is involved in the development and maintenance of normal testicular function. Its role in cell signaling and division, as well as its involvement in the regulation of testicular signaling pathways, make it a potential drug target for the treatment of testicular cancer. Additionally, its use as a biomarker for monitoring the effectiveness of chemotherapy makes it an important tool in the treatment of this disease.

In the future, research into the role of CCT6B as a drug target and biomarker for testicular cancer will continue to be an important area of study. As more research is conducted, it is likely that new treatments will be developed that specifically target this protein and improve the treatment outcomes for those with testicular cancer.

Protein Name: Chaperonin Containing TCP1 Subunit 6B

Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis

The "CCT6B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT6B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84